Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Net (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Receivables - Net readings, the most recent being $366.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 38.24% year-over-year to $366.2 million, compared with a TTM value of $366.2 million through Dec 2025, up 38.24%, and an annual FY2025 reading of $366.2 million, up 38.24% over the prior year.
  • Receivables - Net hit $366.2 million in Q4 2025 for Apellis Pharmaceuticals, up from $345.5 million in the prior quarter.
  • The five-year high for Receivables - Net was $366.2 million in Q4 2025, with the low at $719000.0 in Q2 2021.
  • Median Receivables - Net over the past 5 years was $169.3 million (2023), compared with a mean of $149.4 million.
  • The sharpest move saw Receivables - Net skyrocketed 2580.52% in 2023, then dropped 29.66% in 2025.
  • Year by year, Receivables - Net stood at $10.1 million in 2021, then dropped by 23.76% to $7.7 million in 2022, then soared by 2580.52% to $206.4 million in 2023, then rose by 28.36% to $264.9 million in 2024, then surged by 38.24% to $366.2 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $366.2 million, $345.5 million, and $214.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.